ABOUT CELLAVITA

Cellavita is a clinical stage Biotechnology company operating in Brazil, USA and Israel, focused on the development of Disruptive and Innovative Advanced Cell Therapy Products for the treatment of rare life-threatening diseases, as well as products for significant unmet medical needs.

​

“We are passionate about cells!”

​

We know that there is a significant and unmet need for effective therapies for people whose lives are interrupted by rare, highly debilitating and often fatal diseases.

Using the NestaCell® technology platform, Cellavita® is focused on developing a range of heterologous Advanced Cell Therapy products that can change the lives of people with highly debilitating diseases.

​

Technology Transfer Consulting:

Scientific Committee - Cellavita

​

- Cellavita brought together a group of experts from all over the world to compose a Scientific Committee that will guide clinical investigation for the company from now on, since Cellavita intends to walk with the studies also in a multicenter and International way.

​

This Scientific Committee is composed of the following professionals:

​

-Prof. Dr. Marcondes Cavalcante França Jr. - Unicamp Brazil

-- Dra. Joyce Macedo – Azidus e UFBA / UNIFESP / Unicamp

- Profa. Dra. Elisabeth Quagliato - Unicamp Brazil

- Profa. Dra. Karen Marder - Columbia USA

- Prof Mamede de Carvalho (Lisboa, Portugal)

- Prof Pierre-François Pradat (Paris, France)

- Prof Martin Turner (Oxford, UK)

- Prof Henry Paulson (Michigan, USA)

- Prof Andrew Lees (londres, UK)

- Prof Anthony Lang (Toronto, Canada)